A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer.
about
Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors.Addition of rapamycin and hydroxychloroquine to metronomic chemotherapy as a second line treatment results in high salvage rates for refractory metastatic solid tumors: a pilot safety and effectiveness analysis in a small patient cohortHedgehog signaling drives radioresistance and stroma-driven tumor repopulation in head and neck squamous cancers.Sequencing the head and neck cancer genome: implications for therapyPhase I study of weekly nab-paclitaxel + weekly cetuximab + intensity-modulated radiation therapy (IMRT) in patients with stage III-IVB head and neck squamous cell carcinoma (HNSCC).The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinomaPhase I Study of Everolimus in Combination with Gemcitabine and Split-Dose Cisplatin in Advanced Urothelial CarcinomaThe effect of thymoquinone treatment on the combined renal and pulmonary toxicity of cisplatin and diesel exhaust particlesThe PI3K/Akt/mTOR axis in head and neck cancer: functions, aberrations, cross-talk, and therapies.Novel treatments for head and neck squamous cell carcinoma: preclinical identification and clinical investigation.TEMHEAD: a single-arm multicentre phase II study of temsirolimus in platin- and cetuximab refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO).Investigational drugs for head and neck cancer.Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models.Dysregulations in the PI3K pathway and targeted therapies for head and neck squamous cell carcinomaCetuximab as treatment for head and neck cancer patients with a previous liver transplant: report of two cases.AKT1 restricts the invasive capacity of head and neck carcinoma cells harboring a constitutively active PI3 kinase activity.Significance of mammalian target of rapamycin in patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil.mTOR, metabolism, and the immune response in HPV-positive head and neck squamous cell cancer
P2860
Q27853128-9C68E3BC-0EC0-41EB-A84C-AEE5C817EAEEQ33422577-CD125083-AB77-431C-82C5-83F4051A253BQ34620099-3F32E5DD-6B1D-4DF3-958D-AD0BA26637A7Q35087559-EF9DF18C-5D81-44C7-A16D-1A4ECD36E70CQ35611873-D4030D5E-3BD7-4425-B51B-D53A3FD21CE1Q37046726-24CB9FF7-8C3D-4C1C-AA1C-A7B03F8A0B94Q37053833-9CB81822-D929-47F9-9DC1-A73C64541B78Q37071354-7EB445BD-3D18-42C0-B3B3-BB4A38B4D9D1Q38161944-7E0EC85B-1BB8-44DC-8B1E-CB2260732C96Q38221292-F478F026-620A-45A4-9791-9054F9DA7714Q38388694-0CFFCBC0-44F6-4C35-8850-C1E277A90C4BQ38800788-DA8D5669-C65A-435A-9A8E-D62D1A405E08Q39000880-B231ACD6-3E0E-4061-9278-2A2398042FD2Q39097109-F32BCC01-85D9-4167-A076-E6E8703AA685Q40666475-7A335449-BD62-4263-B99B-B9EDCA5F424CQ51736090-13DF6DB6-688E-4728-BBE4-9BEDCDABEAA8Q54275299-29A7BC8C-F732-4380-854D-E7383823EC44Q57450687-390526F3-6EE4-42A6-AA22-D568578D5A1A
P2860
A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer.
description
2013 nî lūn-bûn
@nan
2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
A phase 1 study of everolimus ...... advanced head and neck cancer.
@ast
A phase 1 study of everolimus ...... advanced head and neck cancer.
@en
type
label
A phase 1 study of everolimus ...... advanced head and neck cancer.
@ast
A phase 1 study of everolimus ...... advanced head and neck cancer.
@en
prefLabel
A phase 1 study of everolimus ...... advanced head and neck cancer.
@ast
A phase 1 study of everolimus ...... advanced head and neck cancer.
@en
P2093
P2860
P356
P1433
P1476
A phase 1 study of everolimus ...... advanced head and neck cancer.
@en
P2093
Adrian Heguy
Camelia Sima
David G Pfister
Eric Sherman
Frank Tsai
Matthew G Fury
Nora Katabi
Oby Nwankwo
P2860
P304
P356
10.1002/CNCR.27986
P407
P577
2013-02-13T00:00:00Z